Jon Stonehouse is retiring as CEO of BioCryst Pharmaceuticals, and Charlie Gayer will assume the role.
1 report, 1 independent
Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jon Stonehouse is retiring as CEO of BioCryst Pharmaceuticals, and Charlie Gayer will assume the role.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioCryst Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmace